Myasthenia Gravis with Horizontal Gaze Palsy

  • An-Guor Wang


A 68-year-old male presented with complaints of sudden-onset lid ptosis and diplopia beginning 3 weeks ago. He denied any past medical history of hypertension or diabetes mellitus. His best-corrected visual acuity was 6/12 OD and 6/15 OS. Eye fissures were found to be 7.5 mm in the right and 6.5 mm in the left. A prism cover test revealed 3 prism diopters of esotropia on primary gaze, which increased to 16 prism diopters on left gaze. Extraocular movements showed moderate limitation on left gaze in both eyes (Fig. 37.1, Video 37.1). Slit lamp examination showed a moderate degree of nuclear sclerosis in both lenses. Fundoscopic examination was normal. A neostigmine test was borderline positive with partial resolution of the gaze palsy at 40 min (Fig. 37.2). MR angiography of the brain demonstrated minimal bilateral stenosis of the distal internal carotid arteries. A peripheral blood examination was ordered, and positive anti-acetylcholine antibody was found (9.02 nmol/L). The patient’s ptosis and diplopia condition improved after the use of Mestinon and prednisolone for 2 weeks (Fig. 37.3). However, he began to occasionally experience dysphagia, easy choking, and chest tightness. An MR imaging of the chest revealed a 3.6 × 1.8 × 5.9 cm mass lesion at the anterior mediastinum, suspected to be thymoma (Fig. 37.4). Surgical removal of the thymoma was done 2 months after onset and pathological report indicated encapsulated thymoma.

Supplementary material

Video 37.1

(MOV 80565 kb)


  1. 1.
    Aydin Y, Ulas AB, Mutlu V, Colak A, Eroglu A. Thymectomy in myasthenia gravis. Eur J Med. 2017;49(1):48–52.Google Scholar
  2. 2.
    Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in Australia. Eur J Neurol. 2012;19:1413–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Vaphiades MS, Bhatti MT, Lesser RL. Ocular myasthenia gravis. Curr Opin Ophthalmol. 2012;23:537–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1):115–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Averbuch-Heller L, Poonyathalang A, von Maydell RD, et al. Hering’s law for eyelids: still valid. Neurology. 1995;45:1781–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Jay WM, Nazarian SM, Underwood DW. Pseudo-internuclear ophthalmoplegia with downshoot in myasthenia gravis. J Clin Neuroophthalmol. 1987;7(2):74–6.PubMedGoogle Scholar
  8. 8.
    Ito K, Mizutani J, Murofushi T, Mizuno M. Bilateral pseudo-internuclear ophthalmoplegia in myasthenia gravis. ORL J Otorhinolaryngol Relat Spec. 1997;59(2):122–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Davis TL, Lavin PJ. Pseudo one-and-a-half syndrome with ocular myasthenia. Neurology. 1989;39(11):1553.CrossRefPubMedGoogle Scholar
  10. 10.
    Appenzeller S, Veilleux M, Clarke A. Third cranial nerve palsy or pseudo 3rd nerve palsy of myasthenia gravis? A challenging diagnosis in systemic lupus erythematosus. Lupus. 2009;18(9):836–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Almog Y, Ben-David M, Nemet AY. Inferior oblique muscle paresis as a sign of myasthenia gravis. J Clin Neurosci. 2016;25:503.CrossRefGoogle Scholar
  12. 12.
    Lepore FE. Divergence paresis: a nonlocalizing cause of diplopia. J Neuroophthalmol. 1999;19(4):242–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Hosaka A, Takuma H, Ohta K, Tamaoka A. An ocular form of myasthenia gravis with a high titer of anti-MuSK antibodies during a long-term follow-up. Intern Med. 2012;51(21):3077–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Wong AME. Eye movement disorders. Oxford: Oxford University Press; 2008. p. 130–1.Google Scholar
  15. 15.
    Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48-49:143–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16:459–67.CrossRefPubMedGoogle Scholar
  17. 17.
    Kupersmith MJ, Moster M, Bhuiyan S, et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996;53:802–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23:251–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Sonett JR, Jaretzki A III. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Ann N Y Acad Sci. 2008;1132:315–28.CrossRefPubMedGoogle Scholar
  20. 20.
    Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology. 1990;40:1828–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156–62.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • An-Guor Wang
    • 1
  1. 1.Department of OphthalmologyTaipei Veterans General Hospital, National Yang-Ming University School of Medicine, Yun-San Ophthalmology Education Research FoundationTaipeiTaiwan

Personalised recommendations